Roche Holding AG research snapshot
ROG AI stock analysis currently reads Roche Holding AG as a Swiss healthcare leader with dual strength in pharmaceuticals and diagnostics, solid first-half 2026 execution, and an improving pipeline anchored by giredestrant, obesity candidates, and divarasib. The analysis is not a certain price prediction. At the August 4, 2026 cutoff, the latest verified close for the ADR equivalent was $54.67 on July 31, 2026, market capitalization was about $348.5 billion, and the main question was whether pipeline approvals and mid-single-digit sales growth can offset biosimilar erosion, Swiss franc appreciation, and a valuation that has risen after a strong 12-month rally. This is informational research and not investment advice.
Current price
$54.67 (ADR close July 31, 2026)
Market cap
$348.5 billion
AI score
74 / 100
Rating
Strong business with improving pipeline and fair valuation
Trend status
Uptrend with price above the 50-day, 100-day, and 200-day moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Roche is the world largest biotech company and a global leader in in-vitro diagnostics, selling prescription medicines and diagnostic instruments across oncology, immunology, neuroscience, and cardiovascular-metabolic care, with recurring revenue from chronic treatments and installed lab systems. First-half 2026 sales grew 6% at constant exchange rates. | High |
| Moat | The moat comes from proprietary oncology drugs, Genentech biologics manufacturing, a diagnostic instrument installed base with switching costs in hospital lab workflows, patient-specific dosing IP, and a century-long brand in global healthcare. | High |
| Management | CEO Thomas Schinecker and Chairman Severin Schwan have maintained R&D leadership and capital discipline. In 2025 Roche advanced 10 molecules into phase III and delivered 12 positive late-stage readouts, and management has restocked the pipeline through deals such as Carmot, 89bio, PathAI, and the Nurix collaboration while raising the dividend for a 39th consecutive year. | Medium-high |
| Financial trend | FY2025 group sales were CHF 61.5 billion (+7% CER) with core operating profit up 13% CER to CHF 21.8 billion, core EPS up 11% CER, and IFRS net income up 58%. First-half 2026 sales rose 6% CER with core EPS up 9% CER, and management confirmed the 2026 outlook of mid-single-digit sales growth and high-single-digit core EPS growth at constant exchange rates. | High |
| Valuation | The ADR traded near 23.7x TTM earnings, 17.7x forward earnings, 4.6x sales, and 14.5x EV/EBITDA with a 2.8% dividend yield at the cutoff. The valuation is fair but not cheap for a mature pharma, and it now prices in meaningful pipeline optionality after the 12-month rally. | Medium |
| Technical trend | The ADR closed at $54.67 on July 31, 2026, above its 50-day ($51.88), 100-day ($51.18), and 200-day ($51.13) moving averages, with a 14-day RSI near 60.7 and ADX near 15.6, indicating a rising but not yet strongly trending market. The 52-week range is $37.51 to $60.85. | Medium-high |
| Risk level | Key risks are accelerating biosimilar erosion on established oncology and autoimmune drugs, sustained Swiss franc appreciation that pressured reported H1 2026 results, China healthcare pricing reforms, late-stage pipeline failures, and drug pricing regulation in the US and Europe. | Medium-high |
| AI confidence | High confidence for the business map, audited financial data, market cap math, and major risk categories. Lower confidence for future stock returns, which depend on pipeline execution, currency, and multiple changes. | High data confidence |
| Investment certainty | Medium certainty. Roche is a defensible business with improving pipeline momentum, but the stock already reflects much of the good news after a strong year, leaving a moderate margin of safety at current levels. | Medium |
ROG AI stock forecast
The ROG AI stock forecast uses scenario ranges around the $54.67 ADR reference price as of the August 4, 2026 cutoff. It does not claim that AI can predict a specific future price. The model starts from a forward earnings base of about $3.09 per ADR implied by the 17.7x forward multiple. The bullish case requires pipeline approvals and obesity progress, the base case assumes steady mid-single-digit sales growth, and the bearish case assumes faster biosimilar erosion, a stronger Swiss franc, or pipeline setbacks.
$64 to $72
More likely if giredestrant is approved on its November 30, 2026 PDUFA date and launches well, the obesity portfolio (enicepatide and petrelintide) advances to phase III with strong data, divarasib gains label momentum, the Swiss franc stabilizes, and the market assigns a higher forward multiple to a re-accelerated growth profile.
$55 to $62
More likely if Roche delivers mid-single-digit sales growth and high-single-digit core EPS growth at constant exchange rates as guided, biosimilar erosion stays at recent pace, pipeline progress continues without a blockbuster surprise, and the stock trades near a 17 to 18x forward multiple.
$42 to $49
More likely if biosimilar erosion accelerates beyond expectations, the Swiss franc appreciates further and cuts reported earnings, giredestrant or the obesity pipeline hits regulatory or commercial setbacks, or China pricing reforms deepen and compress the diagnostics margin.
ROG AI technical analysis
ROG AI technical analysis starts from the $54.67 ADR close on July 31, 2026. Barchart technical snapshots showed the ADR trading above its 50-day, 100-day, and 200-day moving averages with a neutral-to-positive RSI near 60 and ADX below 20, meaning an uptrend is intact but not overextended. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $54.67 | Latest verified ADR close on July 31, 2026, used as the reference for this page as of the August 4, 2026 data cutoff. |
| 52-week range | $37.51 to $60.85 | The ADR traded in this range over the past year, so the all-time-area high near $60.85 is the major upside reference. |
| Near support | $51.80 to $52.85 | The 50-day moving average ($51.88) and 20-day moving average ($52.82) cluster here. A hold above this zone keeps the short-term uptrend intact. |
| Secondary support | $50.00 to $51.20 | The 200-day moving average ($51.13) and the round $50 level. A sustained break below this area would signal a deeper correction. |
| Near resistance | $57.00 to $58.50 | The analyst average price target is $57.23 with a consensus high of $67. This zone represents the next overhead supply after the recent advance. |
| Major resistance | $60.85 | The 52-week high. A volume-confirmed break above it would suggest a new leg higher. |
| 50-day moving average | About $51.88 | Barchart showed the ADR above its 50-day MA near the cutoff, a supportive near-term signal. |
| 200-day moving average | About $51.13 | The ADR was roughly 7% above its 200-day MA, indicating a constructive long-term structure. |
| Momentum | RSI 60.69, ADX 15.58 | RSI was neutral-to-positive. ADX below 20 means the trend is developing but not yet strongly established. |
| Volume | About 1.8M (5-day) to 2.3M (200-day) average shares | Average ADR volume has been steady, with no unusual volume spike at the July 31 close to confirm a breakout. |
| Volatility | ATR 14 near $1.18 (2.14%) | Position sizing should allow for normal daily movement of about 2.1% around the reference price. |
| Invalidation | Close below $51.13 or above $60.85 | A close below the 200-day MA would weaken the bullish structure. A sustained close above $60.85 could signal a new uptrend leg. |
ROG AI trading strategy
The ROG AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels, with a focus on the catalysts that move this specific stock.
Look for ROG to hold above the $51.80 to $52.85 support cluster and to break above $60.85 with rising ADR volume and ADX moving above 20 before treating an uptrend as strongly confirmed.
A failed breakout, a daily close below the 50-day area, or ADX staying below 20 should reduce confidence in directional positioning.
If ROG pulls back toward the $51.80 to $52.85 moving-average cluster or the $50 to $51.20 secondary zone without a thesis break, the pullback can be evaluated against the ~2.8% dividend yield and cash-flow coverage.
Do not buy a falling knife solely because of the dividend. Check biosimilar erosion, the Swiss franc trend, giredestrant PDUFA news, and upcoming earnings before adding.
Track the giredestrant PDUFA date of November 30, 2026, obesity portfolio readouts, H1 and full-year results, diagnostics growth, biosimilar erosion rates, drug pricing regulation, and the CHF/USD exchange rate.
Lower the rating if biosimilar erosion accelerates, late-stage pipeline trials fail, the Swiss franc strengthens sharply, or the market re-rates European pharma to lower multiples.
Investment research summary
Roche turns drug discovery, clinical development, manufacturing, and diagnostic instrumentation into a diversified healthcare cash flow stream, anchored by oncology leadership and hospital lab relationships. First-half 2026 sales grew 6% at constant exchange rates to CHF 30.4 billion.
The moat is proprietary biologics manufacturing, oncology brand heritage, a diagnostic instrument installed base, switching costs in hospital testing workflows, and Genentech research capabilities. Morningstar describes Roche as having a wide moat.
The thesis can fail if the oncology franchise erodes faster than pipeline replacement, giredestrant or the obesity portfolio stumbles, diagnostics faces sustained China pricing pressure, drug pricing regulation compresses margins, or the Swiss franc appreciates and hits reported earnings.
Thomas Schinecker (CEO since 2023) and Severin Schwan (Chairman) have maintained R&D leadership and capital discipline. Management advanced 10 molecules to phase III in 2025, delivered 12 positive late-stage readouts, and raised the dividend for a 39th consecutive year, while restocking the pipeline through Carmot, 89bio, PathAI, and Nurix.
Roche sits at the center of precision medicine, obesity and metabolic care, Alzheimer diagnostic testing, and AI-driven digital pathology. The industry trend is structurally favorable, though drug pricing pressure, biosimilar competition, and currency moves remain persistent headwinds.
At roughly 17.7x forward earnings and a 2.8% dividend yield with an EV/EBITDA near 14.5x, the valuation is reasonable for a mature pharma but does not offer a wide margin of safety after the recent rally. A fair setup needs pipeline approvals to deliver and diagnostics growth to stay stable.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ROG ADR price | $54.67 close on July 31, 2026 | Yahoo Finance RHHBY quote | August 4, 2026 |
| Market capitalization | $348.5 billion intraday, verified as $54.67 x 6,374,000,000 ADR equivalent shares | financial_rigor.py market cap verification | August 4, 2026 |
| 52-week range | $37.51 to $60.85 | Yahoo Finance RHHBY quote | August 4, 2026 |
| FY2025 group sales | CHF 61.5 billion (+7% CER, +2% CHF) | Roche FY2025 investor update, January 29, 2026 | August 4, 2026 |
| FY2025 IFRS net income | CHF 13.8 billion (+58% CER) | Roche FY2025 investor update | August 4, 2026 |
| FY2025 core EPS | CHF 19.46 diluted (+11% CER) | Roche FY2025 investor update | August 4, 2026 |
| FY2025 dividend proposal | CHF 9.80 per share, the 39th consecutive increase | Roche FY2025 investor update | August 4, 2026 |
| H1 2026 group sales | CHF 30.4 billion (+6% CER, -2% CHF, +8% USD), first half of 2026 | Roche H1 2026 ad hoc announcement, July 23, 2026 | August 4, 2026 |
| H1 2026 core EPS | CHF 10.85 diluted (+9% CER, -2% CHF) | Roche H1 2026 ad hoc announcement | August 4, 2026 |
| 2026 outlook | Mid-single-digit sales growth and high-single-digit core EPS growth at CER, dividend increase expected | Roche H1 2026 ad hoc announcement | August 4, 2026 |
| TTM revenue (USD) | $62.96 billion | Yahoo Finance key statistics | August 4, 2026 |
| TTM net income and EPS (USD) | $12.34 billion net income, $2.31 diluted EPS | Yahoo Finance key statistics | August 4, 2026 |
| Cash and free cash flow | $9.73 billion total cash, $10.32 billion levered FCF (TTM) | Yahoo Finance key statistics | August 4, 2026 |
| Valuation math | 23.67x TTM PE, 17.70x forward PE, 8.83x PB, 4.63x PS, 14.45x EV/EBITDA, 2.83% dividend yield, 38.11% ROE | Yahoo Finance key statistics and financial_rigor.py | August 4, 2026 |
| Moving averages and momentum | 50-day MA $51.88, 200-day MA $51.13, RSI 60.69, ADX 15.58, ATR 14 $1.18 | Barchart technical analysis | August 4, 2026 |
| Analyst price targets | Low $46, average $57.23, high $67 | Yahoo Finance analyst insights | August 4, 2026 |
This ROG AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 4, 2026 and can be wrong. Roche Holding AG is listed on the SIX Swiss Exchange under ticker ROG; the price data used in this analysis is from the US ADR (RHHBY) which is a proxy for the economic value of the Swiss-listed shares.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
